STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.
pharmaphorum
APRIL 1, 2022
Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
SEPTEMBER 6, 2023
Known as biosimilars, these biopharma products are highly similar to innovator products and have no clinically meaningful dissimilarities, especially in terms of efficacy, safety or quality. Indian pharma players could play a key role in positioning biosimilars as superior products to costly biologics.
European Pharmaceutical Review
NOVEMBER 8, 2022
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.
Pharmaceutical Technology
FEBRUARY 8, 2023
Roche’s market capitalization fell with a decline in sales of their Regeneron-partnered COVID-19 therapy, Ronapreve, and increasing competition from biosimilars for their oncology drugs Avastin, Herceptin, and Rituxan.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.
Pharmaceutical Technology
SEPTEMBER 26, 2022
The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.
Expert insights. Personalized for you.
363 
Let's personalize your content